Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anthracyclines + paclitaxel
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of anthracyclines (such as doxorubicin or epirubicin) and paclitaxel. Anthracyclines damage DNA inside cancer cells by disrupting enzymes involved in DNA replication, while paclitaxel stabilizes microtubules and prevents their normal dynamic reorganization. This combination is primarily used in the treatment of breast cancer, particularly in metastatic and adjuvant settings.
- Other names
- AC-TAC-TaxolTaxAC
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNA
Beyond the preview
Go deeper on anthracyclines + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anthracyclines + paclitaxel.